Coordinating center for the NCI small cell lung cancer research consortium

NCI 小细胞肺癌研究联盟协调中心

• 批准号: 10091407
• 负责人: Charles M. Rudin
• 金额: $ 107.12万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-02-20 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10091407
• 关键词: Acceleration; Address; Administrative Coordination; Animal Model; Bioinformatics; Biological; Biological Models; Biological Specimen database; Biology; Biometry; CRISPR/Cas technology; Cancer Biology; Cancer Research Project; Cancer cell line; Catalogs; Cell Line; Chemoresistance; Clinical; Collection; Communication; Complement; Complex; Country; Data; Data Analyses; Databases; Development; Diagnosis; Disease; Early Diagnosis; Educational workshop; Epigenetic Process; Fostering; Funding; Funding Opportunities; Gene Expression; Generations; Genetic; Genetic Databases; Genetically Engineered Mouse; Goals; Grant; Health Insurance Portability and Accountability Act; Human; In Vitro; Individual; Leadership; Maintenance; Malignant Neoplasms; Malignant neoplasm of lung; Mentors; Modeling; NIH Program Announcements; Neoplasm Circulating Cells; Patients; Pre-Clinical Model; Prevention; Principal Investigator; Recording of previous events; Reporting; Research; Research Personnel; Research Priority; Resource Sharing; Resources; Secure; Societies; Specimen; Suggestion; Sum; Teleconferences; Therapeutic; Therapeutic Human Experimentation; Tissue Microarray; Tissue Sample; Tissues; Translations; Tumor Tissue; Validation; Work; Xenograft Model; anticancer research; cBioPortal; central database; data exchange; data integration; design; embryonic stem cell; experience; human data; improved; in vitro Model; in vivo; innovation; interest; laboratory experience; lung small cell carcinoma; meetings; member; mouse model; neoplasm resource; novel; novel therapeutics; patient derived xenograft model; pre-clinical; pre-clinical research; programs; repository; resistance mechanism; response; therapeutic development; therapy resistant; tissue resource; tumor; virtual; web site

ABSTRACT The goals of this Coordinating Center include facilitating information exchange among investigators in the NCI Small Cell Lung Cancer (SCLC) Consortium, supporting data integration and data analysis, and serving as a central resource for characterization and distribution of model systems. The leadership of this Center consists of a trio of investigators with deep and long-standing research programs focused on SCLC, with complementary strengths and experience. Charles Rudin, an experienced laboratory and clinical researcher focused on SCLC, who has directed two of the largest lung cancer research programs in the country over the past 13 years, serves as the overall PI of the Center, providing administrative leadership and coordination. John Minna and Tyler Jacks serve as co-leaders of the Center. Dr. Minna has consistently and repeatedly led discovery efforts defining SCLC biology over several decades, and together with his collaborators established nearly all of the SCLC cell lines that have served as the basis for SCLC preclinical research. Dr. Jacks has extensive experience in the development and characterization of innovative genetically engineered mouse models of SCLC and over the past decades has served as the primary mentor of many of the active investigators around the world working on mouse models of SCLC. We bring together additional key investigators and unqiue resources that we believe substantially add to the strengths of the Center. Yu Shir at Vanderbilt has established and directs HIPAA-compliant databases used by several multi- investigator consortia. Nikolaus Schultz’s team developed the cBioPortal and continues to expand and improve this leading platform for analysis and integration of complex –omic level data, supporting many multi- investigator consortia worldwide. Adi Gazdar oversees the cell line resource at UT Southwestern, and will support distribution of these lines to U01 SCLC investigators. Anna Farago and Jeff Engelman at MGH, together with John Poirier and Dr. Rudin at MSK, have established substantial resources of SCLC patient- derived xenografts (PDX) and circulating tumor cell-derived xenografts (CDX) models, which are available for distribution among consortium members. Scott Lowe and Andrea Ventura offer highly innovative genetically engineered mouse modeling by CRISPR/Cas9 modulation of embryonic stem cells to rapidly assess genetic contributors to SCLC biology. Afshin Dowlati at Case Western will contribute a large collection of clinically annotated SCLC tissue microarrays representing chemosensitive as well as primary and secondary chemoresistant disease. Together we represent an exceptional team, led by three of the most widely recognized and established investigators in SCLC discovery research, with complementary strengths in therapeutic translation, basic biology, and animal modeling. By providing the resources above, and by coordinating frequent data-sharing opportunities and leading annual face-to-face meetings among SCLC investigators, we believe this Center can substantially accellerate progress against this deadly disease.

抽象的 该协调中心的目标包括促进调查人员之间的信息交流 NCI 小细胞肺癌 (SCLC) 联盟，支持数据集成和数据分析，以及 作为模型系统的表征和分发的中心资源。 该中心由三名研究人员组成，他们的研究项目专注于 SCLC、 Charles Rudin 具有互补的优势和经验，是一位经验丰富的实验室和临床人员。 专注于小细胞肺癌 (SCLC) 的研究人员，曾指导过美国两个最大的肺癌研究项目 13年来，作为中心的总体PI，提供行政领导和 约翰·明纳 (John Minna) 和泰勒·杰克斯 (Tyler Jacks) 一直担任该中心的联合领导。 几十年来，多次领导定义 SCLC 生物学的发现工作，并与他一起 合作者建立了几乎所有的 SCLC 细胞系，这些细胞系已成为 SCLC 临床前的基础 Jacks 博士在创新的开发和表征方面拥有丰富的经验。 SCLC 的基因工程小鼠模型，并在过去几十年中一直担任主要导师 我们汇集了世界各地从事 SCLC 小鼠模型研究的许多活跃研究人员。 我们认为额外的关键调查员和独特的资源大大增强了该中心的优势 范德堡大学的 Yu Shir 中心建立并指导了多个多方使用的符合 HIPAA 的数据库。 Nikolaus Schultz 的团队开发了 cBioPortal 并继续扩展和发展。 改进这个领先的平台，用于分析和集成复杂的组学级数据，支持许多多 Adi Gazdar 负责监督 UT 西南大学的细胞系资源，并将 支持将这些线路分发给 MGH 的 U01 SCLC 研究人员 Anna Farago 和 Jeff Engelman， 与 MSK MSK 的 John Poirier 和 Rudin 博士一起，建立了丰富的 SCLC 患者资源- 衍生的异种移植物（PDX）和循环肿瘤细胞衍生的异种移植物（CDX）模型，可用于 Scott Lowe 和 Andrea Ventura 提供高度创新的基因分配。 通过 CRISPR/Cas9 调节胚胎干细胞进行工程小鼠建模，以快速评估遗传 Case Western 的 SCLC 生物学贡献者 Afshin Dowlati 将贡献大量临床资料。 带注释的 SCLC 组织微阵列代表化学敏感性以及原发性和继发性 我们共同代表了一支杰出的团队，由三位最广泛的人领导。 SCLC 发现研究领域公认的知名研究者，在以下方面具有互补优势 通过提供上述资源以及通过翻译、基础生物学和动物治疗模型。 协调 SCLC 之间频繁的数据共享机会并主持年度面对面会议 研究人员，我们相信该中心可以大大加快对抗这种致命疾病的进展。